Product image of Korjuny (Catumaxomab) supplied by GNH India

Korjuny

Active Ingredient:
Catumaxomab
Origin:
EU

Korjuny (Catumaxomab)

Catumaxomab, the active ingredient in Korjuny, is a monoclonal antibody (bispecific/trifunctional) presented as a solution for intraperitoneal infusion for intraperitoneal use. It treats malignant ascites associated with EpCAM‑positive carcinomas in patients with peritoneal tumor burden.

GNH India supplies Korjuny as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Atnahs Pharma Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Korjuny is indicated for the management of malignant ascites and related peritoneal disease states that express EpCAM.

  • Malignant ascites associated with EpCAM‑positive carcinomas: reduces fluid accumulation and improves patient comfort.
  • Peritoneal carcinomatosis from ovarian carcinoma: helps control tumor burden within the abdominal cavity.
  • Gastric carcinoma with peritoneal spread: contributes to symptom control and limits disease progression.

How It Works

  • Catumaxomab binds EpCAM on tumor cells and CD3 on T cells while simultaneously engaging Fcγ receptors on accessory immune cells. This tri‑functional binding creates a bridge that activates T cells and recruits innate immune effectors, leading to coordinated immune‑mediated tumor cell lysis within the peritoneal cavity.

Side Effects

Common Side Effects

  • Fever: transient elevation of body temperature after infusion.
  • Abdominal pain: mild to moderate discomfort in the treated area.
  • Nausea and vomiting: gastrointestinal upset following administration.
  • Chills and rigors: shaking sensations during or shortly after infusion.
  • Fatigue: general tiredness reported by patients.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Hypersensitivity reactions: including rash, urticaria, or anaphylaxis.
  • Cytokine release syndrome: systemic inflammatory response with fever and hypotension.
  • Peritonitis: inflammation of the peritoneal lining.
  • Severe infection: opportunistic infections due to immune modulation.
  • Hepatic toxicity: elevated liver enzymes or liver injury.
  • Neutropenia: reduced neutrophil count increasing infection risk.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Monitor infusion reactions: observe patients during and after infusion for signs of hypersensitivity.
  • Assess hepatic function: check liver enzymes prior to treatment and periodically thereafter.
  • Evaluate immune status: be cautious in patients with existing immunosuppression.
  • Avoid in known hypersensitivity to murine proteins: contraindicated for patients with documented allergy.
  • Use caution with active infections: defer treatment until infection is controlled.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Catumaxomab may interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid)

  • Concurrent use with other immunomodulatory antibodies: risk of additive immune activation.
  • Live vaccines: may cause uncontrolled infection due to immune suppression.
  • Cytotoxic chemotherapy: potential for increased toxicity and overlapping adverse effects.
  • Systemic steroids: may diminish therapeutic efficacy.
  • High‑dose immunoglobulins: could interfere with antibody binding.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: monitor for bleeding tendencies.
  • Antifungal agents metabolized by hepatic pathways: watch for altered drug levels.
  • NSAIDs: increased risk of gastrointestinal irritation when combined with infusion‑related nausea.

Frequently Asked Questions

Korjuny is a biologic therapy indicated for the treatment of malignant ascites associated with EpCAM‑positive carcinomas, such as ovarian, gastric, and colorectal cancers. It is used to reduce peritoneal fluid buildup and help control tumor burden within the abdominal cavity.

Catumaxomab is a trifunctional monoclonal antibody that simultaneously binds EpCAM on tumor cells, CD3 on T‑cells, and Fcγ receptors on accessory immune cells. This creates a bridge that activates both adaptive and innate immune responses, leading to targeted destruction of tumor cells in the peritoneal space.

The dosing regimen for Korjuny is individualized and determined by the prescribing oncologist based on the patient’s clinical condition, tumor type, and treatment protocol. Specific dosage amounts and infusion schedules are not publicly disclosed and should be obtained from the treating physician.

Safety data for catumaxomab in pregnancy and lactation are limited. Because the drug can affect the immune system, it is generally not recommended for use in pregnant or nursing women unless the potential benefit outweighs the potential risk, as assessed by the treating physician.

To place an order, visit the product page for Korjuny on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Korjuny’s bispecific antibody mechanism differs from conventional chemotherapy or paracentesis by directly engaging the patient’s immune system to target EpCAM‑positive tumor cells. While other intraperitoneal agents may rely on cytotoxic effects, catumaxomab offers a targeted immunotherapeutic approach, which can result in different efficacy and safety profiles.

Korjuny should be stored refrigerated at 2‑8 °C. It must be kept in its original container, protected from light, and should never be frozen or shaken. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Korjuny is given as an intraperitoneal infusion. The solution is administered directly into the peritoneal cavity, typically by a trained healthcare professional in a clinical setting, following the dosing schedule prescribed by the oncologist.

Serious risks include hypersensitivity reactions such as anaphylaxis, cytokine release syndrome, severe infections, hepatic toxicity, and neutropenia. Patients should be closely monitored during and after infusion for any signs of these adverse events, and appropriate medical intervention should be available.

Korjuny is contraindicated in patients with known hypersensitivity to catumaxomab or any murine protein components, those with active uncontrolled infections, and individuals receiving live vaccines. Caution is also advised for patients with severe hepatic impairment or existing severe immune disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Catumaxomab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT